CL2022002699A1 - Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton. - Google Patents
Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton.Info
- Publication number
- CL2022002699A1 CL2022002699A1 CL2022002699A CL2022002699A CL2022002699A1 CL 2022002699 A1 CL2022002699 A1 CL 2022002699A1 CL 2022002699 A CL2022002699 A CL 2022002699A CL 2022002699 A CL2022002699 A CL 2022002699A CL 2022002699 A1 CL2022002699 A1 CL 2022002699A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- multiple sclerosis
- tyrosine kinase
- kinase inhibitor
- relapsing multiple
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005095P | 2020-04-03 | 2020-04-03 | |
| US202063051767P | 2020-07-14 | 2020-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022002699A1 true CL2022002699A1 (es) | 2023-03-31 |
Family
ID=75625678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022002699A CL2022002699A1 (es) | 2020-04-03 | 2022-09-30 | Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12605376B2 (https=) |
| EP (1) | EP4125906A1 (https=) |
| JP (1) | JP2023520469A (https=) |
| KR (1) | KR20220163986A (https=) |
| CN (1) | CN115916205A (https=) |
| AU (1) | AU2021249129A1 (https=) |
| BR (1) | BR112022019846A2 (https=) |
| CA (1) | CA3177390A1 (https=) |
| CL (1) | CL2022002699A1 (https=) |
| IL (1) | IL296990A (https=) |
| MX (1) | MX2022012310A (https=) |
| TW (1) | TWI907406B (https=) |
| WO (1) | WO2021202825A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022010513A (es) * | 2020-02-28 | 2022-09-21 | Genentech Inc | Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. |
| KR102933902B1 (ko) | 2021-05-14 | 2026-03-05 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 공결정질 형태 |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
| WO2024238524A1 (en) * | 2023-05-16 | 2024-11-21 | Genentech, Inc. | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| SG11201700849XA (en) | 2014-08-07 | 2017-03-30 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor |
| EP4049660B1 (en) | 2016-02-29 | 2025-02-19 | F. Hoffmann-La Roche AG | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| CN107043366B (zh) | 2017-04-25 | 2020-05-26 | 中国药科大学 | 4-氨基嘧啶类化合物、其制备方法及医药用途 |
| MX393601B (es) | 2017-05-18 | 2025-03-21 | Jiangsu Hengrui Medicine Co | Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores. |
| WO2019208805A1 (ja) * | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
| CN112512527A (zh) * | 2018-09-12 | 2021-03-16 | 杭州索元生物医药股份有限公司 | 恩扎妥林和btk抑制剂的组合及其用途 |
| CN113423401A (zh) | 2019-01-22 | 2021-09-21 | 豪夫迈·罗氏有限公司 | 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法 |
| MX2022010513A (es) | 2020-02-28 | 2022-09-21 | Genentech Inc | Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. |
-
2021
- 2021-04-01 AU AU2021249129A patent/AU2021249129A1/en active Pending
- 2021-04-01 IL IL296990A patent/IL296990A/en unknown
- 2021-04-01 TW TW110112266A patent/TWI907406B/zh active
- 2021-04-01 CN CN202180035499.8A patent/CN115916205A/zh active Pending
- 2021-04-01 EP EP21720649.9A patent/EP4125906A1/en active Pending
- 2021-04-01 WO PCT/US2021/025301 patent/WO2021202825A1/en not_active Ceased
- 2021-04-01 JP JP2022559934A patent/JP2023520469A/ja active Pending
- 2021-04-01 MX MX2022012310A patent/MX2022012310A/es unknown
- 2021-04-01 KR KR1020227037384A patent/KR20220163986A/ko active Pending
- 2021-04-01 BR BR112022019846A patent/BR112022019846A2/pt unknown
- 2021-04-01 CA CA3177390A patent/CA3177390A1/en active Pending
- 2021-04-01 US US17/995,259 patent/US12605376B2/en active Active
-
2022
- 2022-09-30 CL CL2022002699A patent/CL2022002699A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12605376B2 (en) | 2026-04-21 |
| KR20220163986A (ko) | 2022-12-12 |
| BR112022019846A2 (pt) | 2022-11-22 |
| CA3177390A1 (en) | 2021-10-07 |
| WO2021202825A1 (en) | 2021-10-07 |
| MX2022012310A (es) | 2022-10-27 |
| CN115916205A (zh) | 2023-04-04 |
| US20230149395A1 (en) | 2023-05-18 |
| TWI907406B (zh) | 2025-12-11 |
| IL296990A (en) | 2022-12-01 |
| EP4125906A1 (en) | 2023-02-08 |
| TW202203925A (zh) | 2022-02-01 |
| JP2023520469A (ja) | 2023-05-17 |
| AU2021249129A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022002699A1 (es) | Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton. | |
| MX2022012714A (es) | Inhibidores de la replicacion de norovirus y coronavirus. | |
| UY39529A (es) | Nuevos agentes antivirales derivados de espiropirrolidina | |
| MX2022012285A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| BR112022014058A2 (pt) | Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms) | |
| UY28041A1 (es) | Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial. | |
| AR119158A1 (es) | Tratamientos de angioedema hereditario | |
| DE60215787D1 (de) | Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern | |
| AR083957A1 (es) | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica | |
| ES2144119T3 (es) | Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada. | |
| BR112022026186A2 (pt) | Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras | |
| FI3972603T3 (fi) | Menetelmiä sjögrenin oireyhtymän hoitamiseksi käyttäen brutonin tyrosiinikinaasin estäjää | |
| CL2022002317A1 (es) | Métodos para tratar esclerosis múltiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. | |
| MX2024001540A (es) | Inhibidores para coronavirus. | |
| ECSP22081150A (es) | Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica | |
| AR126166A1 (es) | Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos | |
| AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
| UY39864A (es) | Nuevos agentes antivirales derivados de espiropirrolidina | |
| BR0111158A (pt) | Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| ES2582660T3 (es) | Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina | |
| BR112022007616A2 (pt) | Métodos e composições para tratar doença falciforme com um inibidor de ferroportina (vit-2763) | |
| MX2021009488A (es) | Uso de vibegron para tratar la vejiga hiperactiva. | |
| MX2023014898A (es) | Terapia combinada anti-vhc ventajosa. |